eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Thornton & Ross Ltd

Telephone: +44 (0)1484 842217
Fax: +44 (0)1484 847301
WWW: http://www.thorntonandross.com
Medical Information Direct Line: +44(0)1484 848 251
Medical Information e-mail: phv@thorntonross.co.uk
Customer Care direct line: +44(0)1484 842 217
Medical Information Fax: +44(0)1484 847 301

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 07/11/2011
SPC Eucalyptus Oil BP


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Eucalyptus Oil BP


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Eucalyptus Oil BP 100.0% v/v.


Go to top of the page
3. PHARMACEUTICAL FORM

Essential Oil.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

1. For relief of the symptoms of catarrhal colds.

2. For relief of the symptoms of minor muscular sprains and cramps


Go to top of the page
4.2 Posology and method of administration

1. a) By inhalation from drops of oil spilled onto a handkerchief which is then sniffed.

b) By inhalation of vapour from drops of oil spilled into a bowl of hot water (50°C) 'steam inhalation' and the humid vapour inhaled.

2. As a rubefacient during massage of sprains and cramps where massage is an appropriate treatment.

Recommended Dose and Dosage Schedule

Adults, the elderly and children over 1 year:

1 a) Sprinkle a few drops on to a handkerchief and inhale as required.

b) A few drops into warm/hot water (50°C) and inhale the humid vapour, as required.

2. A few drops on the hand to lubricate the massage of appropriate areas as required.


Go to top of the page
4.3 Contraindications

Sensitivity to Eucalyptus Oil.

Not recommended for infants under 1 year.


Go to top of the page
4.4 Special warnings and precautions for use

Keep all medicines out of the reach and sight of children.

Not to be take orally.

If symptoms persist consult your doctor


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known


Go to top of the page
4.6 Pregnancy and lactation

No evidence can be found as to the safety of the product in pregnancy or lactation. The use of all drugs should be avoided during the first trimester.


Go to top of the page
4.7 Effects on ability to drive and use machines

At the dosage indicated, no evidence can be found that the product affects the ability to drive or to use machinery


Go to top of the page
4.8 Undesirable effects

When used as a rubefacient it may induce skin sensitisation and eczema.

No adverse effects of inhalation are reported but in sensitised individuals the precipitation of hay fever or asthma are potential unwanted effects


Go to top of the page
4.9 Overdose

Symptoms: poisoning with eucalyptus oil may cause epigastric burning, nausea and vomiting, dizziness, muscular weakness, miosis, tachycardia, a feeling of suffocation, cyanosis, ataxia, pulmonary damage, delirium, convulsions and CNS depression, including coma. Deaths have been recorded from doses as low as 3.5ml.

Emergency procedures: after ingestion the stomach should be emptied by aspiration and lavage. Demulcent drinks may be given. Large volumes of fluid should be given provided renal function is adequate. Effects of excessive inhalation should be treated by removal to fresh air.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

When the vapour is inhaled eucalyptus oil acts to ventilate the bronchial passages and relieve bronchitis and associated conditions. It is also a rubefacient.


Go to top of the page
5.2 Pharmacokinetic properties

After ingestion excretion takes place via the lungs, skin and kidneys.


Go to top of the page
5.3 Preclinical safety data

None


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

None


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

14ml:

36 months unopened.

25ml:

36 months unopened.

50ml:

36 months unopened.

500ml:

36 months unopened.

2000ml:

36 months unopened


Go to top of the page
6.4 Special precautions for storage

Store below 25°C.

Keep container tightly closed


Go to top of the page
6.5 Nature and contents of container

14ml: Oval, ribbed, white glass bottle with plastic cap.

25ml, 50ml, 500ml, and 2000ml: Amber glass bottle with plastic cap, or white plastic child resistant cap with EPE/Saranex liner.


Go to top of the page
6.6 Special precautions for disposal and other handling

None


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

L. C. M. Ltd.

Linthwaite Laboratories

Huddersfield

HD7 5QH


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 12965/0011


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

13.04.94/21.05.99


Go to top of the page
10. DATE OF REVISION OF THE TEXT

20.12.03


Go to top of the page
11 DOSIMETRY (IF APPLICABLE)

Not Applicable


Go to top of the page
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)

Not Applicable



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/25204/SPC/


Active Ingredients/Generics

 
   eucalyptus oil